PMDA drug package insert
テビケイ錠50mg
PMDA Prescription drug · ヴィーブヘルスケア株式会社 · package insert Aug 25, 2026
Key facts
| Brand names | テビケイ錠50mg |
|---|---|
| Nonproprietary names | ドルテグラビルナトリウム |
| Companies | 製造販売元／ヴィーブヘルスケア株式会社, 販売元／グラクソ・スミスクライン株式会社 |
| Product type | Prescription drug |
| Therapeutic category | HIVインテグラーゼ阻害剤 |
| Therapeutic category codes | 87625 |
| YJ codes | 6250038F1023 |
| Approval numbers | 22600AMX00561 |
| Package insert edition | 第9版 |
| Package insert date | Aug 25, 2026 |
| PMDA document key | 166272_6250038F1023_1 |
| PMDA company code | 166272 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: